A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

Phase 1TerminatedNCT06435039

Syneos Health12 enrolled

Overview

The primary objective of the study is to assess safety and tolerability following administration of single doses of APL-1202 (immediate release) IR tablets and APL-1501 extended release (ER) capsules in healthy participants.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy Volunteers

Interventions

APL-1202DRUG

APL-1202 IR tablets.

APL-1501DRUG

APL-1501 ER capsules.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Participants must meet all of the following criteria to be included in the study: 1. Male, \>=18 and less than or equal to (\<=) 65 years of age, with body mass index (BMI) greater than (\>) 18.5 and less than (\<) 32.0 kilogram per square meter (kg/m\^2) and body weight \>=50.0 kilogram (kg). 2. Non-smoker (no use of tobacco or nicotine products, example, snuff, chewing tobacco, cigars, cigarettes, pipes, e-cigarettes \[vaping\] etc. within 3 months prior to screening). 3. Healthy as defined by: 1. the absence of clinically significant illness and surgery within 4 weeks prior to study drug administration. 2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease. 4. Sexually active non-sterile males must be willing to use an acceptable contraceptive method throughout the study. 5. Able to understand the study procedures and provide signed informed consent to participate in the study. Exclusion Criteria: Participants to whom any of the following applies will be excluded from the study: 1. Any clinically significant abnormal finding at physical examination. 2. Clinically significant abnormal laboratory test results or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV) antibody, or Human immunodeficiency virus (HIV) antigen and antibody. 3. Positive urine drug screen, cotinine test, or alcohol breath test. 4. History of significant allergic reactions (example, anaphylactic reaction, hypersensitivity, angioedema) to any drug. 5. Clinically significant Electrocardiograms (ECG) abnormalities or vital signs abnormalities (systolic blood pressure \[BP\] lower than 90 or over 140 millimeters of mercury \[mmHg\], diastolic BP lower than 50 or over 90 mmHg, heart rate \[HR\] less than 40 or over 100 beats per minute \[bpm\], or RR less than 10 or over 25 bpm) at screening. 6. History of drug abuse within 1 year prior to screening or recreational use of marijuana within 1 month or other illegal drugs such as cocaine, phencyclidine \[PCP\], crack, opioid derivatives including heroin, and amphetamine derivatives within 3 months prior to screening. 7. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units of alcohol per week (1 unit = 375 milliliter \[mL\] of beer 3.5 percent (%), or 100 mL of wine 13.5%, or 30 mL of distilled alcohol 40%). 8. Use of medications within the timeframes specified in section. 9. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration. 10. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing. 11. Optic nerve disease, cataracts, or a history of related conditions. 12. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.

Locations (1)

Scientia Clinical Research Ltd

Randwick, New South Wales, Australia

Outcomes

Primary Outcomes

Number of Participants With Adverse Events (AEs)

Time frame: From Baseline up to Day 9

Number of Participants With Abnormal Vital Sign Measurements

Time frame: From Baseline up to Day 9

Number of Participants With Abnormal 12-Lead Electrocardiogram (ECGs) Recordings

Time frame: From Baseline up to Day 9

Number of Participants With Abnormal Physical Examinations

Time frame: From Baseline up to Day 9

Number of Participants With Abnormal Clinical Laboratory Values

Time frame: From Baseline up to Day 9

Secondary Outcomes

AUC0-t: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration of APL-1202, and ASN-1651 (Metabolite) Following APL-1501 ER Capsules